Jul. 14 at 5:27 AM
$RIGL Worth remembering: while VEPPANU's exact development cost has never been publicly disclosed, around
$1.X billion is a realistic estimate for a novel oncology drug when you include discovery, preclinical research, Phase 1-3 clinical trials, failed programs, and the cost of capital. Several recent studies estimate average development costs in the
$1.0-1.3 billion range, with some oncology analyses even higher.
This highlights why Rigel's acquisition is so compelling. Rigel obtained a fully FDA-approved asset without having to spend years bearing most of the development costs and risks. The focus now is on successful commercialization and maximizing VEPPANU's value alongside TAVALISSE, REZLIDHIA, GAVRETO royalties, and the rest of the pipeline.
